Genpharmasec Ltd Stock Price Today (NSE: GENPHARMA)
Fundamental Score
Genpharmasec Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Genpharmasec Ltd share price today is ₹1.18, up +0.00% on NSE/BSE as of 22 June 2026. Genpharmasec Ltd (GENPHARMA) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of ₹81.95 (Cr). The 52-week high for GENPHARMA share price is ₹2.20 and the 52-week low is ₹0.75. At a P/E ratio of 149.01x, GENPHARMA is currently trading above its industry average P/E of 35.45x. The company has a Return on Equity (ROE) of 1.90% and a debt-to-equity ratio of 0.17.
Genpharmasec Ltd Share Price Chart — NSE/BSE Historical Performance
Genpharmasec Ltd share price chart: -2.34% return over the past month. 52-week high ₹2.20, 52-week low ₹0.75.
Genpharmasec Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1.19 | ₹1.22 | ₹1.16 | ₹1.18 | 5.25L (Cr) | |
| ₹1.20 | ₹1.21 | ₹1.16 | ₹1.18 | 3.21L (Cr) | |
| ₹1.19 | ₹1.29 | ₹1.19 | ₹1.19 | 10.73L (Cr) | |
| ₹1.31 | ₹1.33 | ₹1.25 | ₹1.25 | 6.32L (Cr) | |
| ₹1.34 | ₹1.34 | ₹1.25 | ₹1.31 | 17.20L (Cr) | |
| ₹1.28 | ₹1.28 | ₹1.28 | ₹1.28 | 6.52L (Cr) | |
| ₹1.22 | ₹1.22 | ₹1.22 | ₹1.22 | 5.11L (Cr) | |
| ₹1.20 | ₹1.20 | ₹1.14 | ₹1.17 | 1.45L (Cr) | |
| ₹1.12 | ₹1.20 | ₹1.12 | ₹1.15 | 1.34L (Cr) | |
| ₹1.15 | ₹1.18 | ₹1.13 | ₹1.16 | 2.00L (Cr) |
Genpharmasec Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1.20 | ₹1.22 | ₹1.16 | ₹1.18 | -1.67% | |
| ₹1.25 | ₹1.34 | ₹1.09 | ₹1.19 | -4.80% | |
| ₹0.80 | ₹1.34 | ₹0.80 | ₹1.22 | +52.50% | |
| ₹1.14 | ₹1.23 | ₹0.75 | ₹0.78 | -31.58% | |
| ₹1.11 | ₹1.45 | ₹1.11 | ₹1.18 | +6.31% | |
| ₹1.34 | ₹1.40 | ₹1.06 | ₹1.17 | -12.69% | |
| ₹1.53 | ₹1.56 | ₹1.29 | ₹1.31 | -14.38% | |
| ₹1.63 | ₹1.79 | ₹1.42 | ₹1.52 | -6.75% | |
| ₹1.90 | ₹1.92 | ₹1.58 | ₹1.61 | -15.26% | |
| ₹1.97 | ₹2.15 | ₹1.85 | ₹1.90 | -3.55% | |
| ₹2.00 | ₹2.20 | ₹1.91 | ₹1.94 | -3.00% | |
| ₹2.07 | ₹2.09 | ₹1.84 | ₹1.99 | -3.86% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Micro-cap pharma distributor's acquisition is a value trap until proven otherwise.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The company held an independent director's meeting on March 24, 2026, to review board performance and information flow.
CORE STORY (THE REAL GAME)
- Standalone revenue growth is strong, but misleading
- Acquisition integration is a mess
- Micro-cap liquidity risk
- Successful Derren Healthcare integration
- New large distribution contracts
- Significant cost-cutting measures
- Micro-cap: high liquidity risk
- Poor profitability despite revenue growth
- Acquisition integration issues
No FII/DII activity. Promoter holding stable at 29.98%.
Trading & distribution sector faces intense competition and margin pressure.
No Free Cash Flow reported.
Next 3-6 months hinge on Derren Healthcare turnaround. Expect continued volatility and potential for significant downside if integration fails.
Primary Thesis Risk
Derren Healthcare acquisition destroys shareholder value.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Genpharmasec Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Genpharmasec Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GENPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (441.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.90%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 149.01x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-268.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Low Promoter Commitment (29.98%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Genpharmasec Ltd vs Trading & Distributors Peers
Peer Comparison - Trading & Distributors
Compare Genpharmasec Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Genpharmasec LtdGenpharmasec Lt...Selected✓ GENPHARMA • 531592 | 11/100 | ₹1.18₹1 | ₹81.95₹81.95 | 149.01Average 149.0 Average | 1.90%Poor 1.90% Poor | 3.35%Poor 3.35% Poor | 0.17Excellent 0.2 Excellent | — — | — — | 0.00% |
Redington LtdRedington Ltd... REDINGTON • 532805 | 58.5/100 | ₹222.80₹223 | ₹22049.92₹22049.92 | 16.14Average 16.1 Average | 14.39%Average 14.39% Average | 18.90%Good 18.90% Good | 0.29Excellent 0.3 Excellent | 17.72%Excellent 17.72% Excellent | 14.06%Good 14.06% Good | 2.41% |
MMTC LtdMMTC Ltd... MMTC • 513377 | 32.1/100 | ₹65.99₹66 | ₹8949.04₹8949.04 | 127.30Average 127.3 Average | 5.87%Poor 5.87% Poor | 7.70%Poor 7.70% Poor | 0.02Excellent 0.0 Excellent | 19.08%Excellent 19.08% Excellent | -86.52%Poor -86.52% Poor | 0.00% |
MSTC LtdMSTC Ltd... MSTCLTD • 542597 | 63.7/100 | ₹438.75₹439 | ₹3458.41₹3458.41 | 15.65Average 15.7 Average | 28.37%Excellent 28.37% Excellent | 29.26%Excellent 29.26% Excellent | 0.17Excellent 0.2 Excellent | 15.18%Excellent 15.18% Excellent | -24.06%Poor -24.06% Poor | 8.24% |
BN Holdings LtdBN Holdings Ltd... BNHOLDINGS • 526125 | 24.7/100 | ₹404.70₹405 | ₹3333.57₹3333.57 | 49.50Average 49.5 Average | 26.05%Excellent 26.05% Excellent | 27.44%Excellent 27.44% Excellent | 0.20Excellent 0.2 Excellent | — — | — — | 0.00% |
Vintage Coffee And Beverages IncVintage Coffee ... VINCOFE • 538920 | 11.1/100 | ₹154.05₹154 | ₹2132.64₹2132.64 | 35.45Average 35.5 Average | 17.05%Good 17.05% Good | 15.42%Good 15.42% Good | 0.17Excellent 0.2 Excellent | — — | — — | 0.06% |
TCC Concept LtdTCC Concept Ltd... TCC • 512038 | 34.8/100 | ₹379.00₹379 | ₹1813.06₹1813.06 | 38.36Average 38.4 Average | 9.28%Poor 9.28% Poor | 11.83%Average 11.83% Average | 0.05Excellent 0.1 Excellent | — — | — — | 0.00% |
Euro Asia Exports LtdEuro Asia Expor... EUROASIA • 530929 | 66.6/100 | ₹637.25₹637 | ₹1297.46₹1297.46 | 518.98Average 519.0 Average | 87.02%Excellent 87.02% Excellent | 82.72%Excellent 82.72% Excellent | 0.00Excellent 0.0 Excellent | 158.76%Excellent 158.76% Excellent | 66.77%Excellent 66.77% Excellent | 0.00% |
41.9/100 | ₹18.76₹19 | ₹1111.34₹1111.34 | 402.66Average 402.7 Average | 1.24%Poor 1.24% Poor | 2.46%Poor 2.46% Poor | 0.06Excellent 0.1 Excellent | 61.76%Excellent 61.76% Excellent | 35.83%Excellent 35.83% Excellent | 0.00% | |
Yamuna Syndicate LtdYamuna Syndicat... YSL • 540980 | 32.3/100 | ₹30300.00₹30300 | ₹1021.99₹1021.99 | 11.71Average 11.7 Average | 9.31%Poor 9.31% Poor | 9.39%Poor 9.39% Poor | 0.00Excellent 0.0 Excellent | 10.82%Good 10.82% Good | 4.86%Average 4.86% Average | 1.50% |
Oswal Agro Mills LtdOswal Agro Mill... OSWALAGRO • 500317 | 62.3/100 | ₹45.83₹46 | ₹811.32₹811.32 | 6.43Average 6.4 Average | 12.62%Average 12.62% Average | 16.29%Good 16.29% Good | 0.00Excellent 0.0 Excellent | 28.35%Excellent 28.35% Excellent | 61.75%Excellent 61.75% Excellent | 0.00% |
Top Trading & Distributors Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Redington Ltd share price22049.92 Cr
- MMTC Ltd share price8949.04 Cr
- MSTC Ltd share price3458.41 Cr
- BN Holdings Ltd share price3333.57 Cr
- Vintage Coffee And Beverages Inc share price2132.64 Cr
Genpharmasec Ltd PE Ratio History
Historical price-to-earnings ratio for GENPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.01 | ₹1.31 | 131x |
| FY 2024 | ₹0.01 | ₹3.08 | 308x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Genpharmasec Ltd Quarterly Performance
Latest quarterly metrics for GENPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
441.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-268.57%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Genpharmasec Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GENPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Genpharmasec Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Genpharmasec Ltd (GENPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Genpharmasec Ltd
About GENPHARMA (Genpharmasec Ltd)
Genpharmasec Ltd is a dynamic enterprise operating at the intersection of pharmaceutical distribution and strategic investments. The company facilitates the seamless flow of vital ...pharmaceutical resources, connecting manufacturers with healthcare providers across the Indian landscape. Genpharmasec functions as a key logistical partner, ensuring the reliable and efficient delivery of medical necessities to where they are needed most. Beyond simply moving products, Genpharmasec is deeply engaged in understanding and navigating the complexities of the pharmaceutical market, adapting to its ever-evolving demands and regulatory framework. This proactive approach allows them to capitalize on emerging opportunities and provide tailored solutions to both suppliers and customers, fostering strong and enduring relationships within the healthcare ecosystem. A critical component of Genpharmasec's operations lies in its specialized distribution of diagnostic pharmaceutical equipment. Notably, this includes sophisticated tools like i-STAT analyzers and associated cartridges, essential for rapid blood analysis in critical care settings. By making these advanced diagnostic tools readily available, Genpharmasec directly contributes to the enhancement of patient care within Intensive Care Units (ICUs) and other acute care facilities. Their commitment to supplying cutting-edge diagnostic technology reflects a dedication to improving the speed and accuracy of medical assessments, enabling healthcare professionals to make informed decisions and deliver timely interventions. This targeted approach to diagnostic equipment distribution highlights Genpharmasec's focus on meeting the specialized needs of critical care environments. Furthermore, Genpharmasec Ltd engages in strategic investment and trading within the securities market. This facet of the company's activities demonstrates a diversification strategy aimed at generating value and strengthening its overall financial position. By actively participating in the financial markets, Genpharmasec seeks to optimize its resources and enhance its ability to support its core pharmaceutical distribution operations. This financial acumen enables the company to reinvest in its infrastructure, expand its product portfolio, and explore new avenues for growth and innovation. The synergy between its pharmaceutical distribution expertise and its investment activities positions Genpharmasec as a multifaceted organization with a long-term vision for sustainable success.
Company Details
Key Leadership
Latest News
GENPHARMA Share Price: Frequently Asked Questions
What is the current share price of Genpharmasec Ltd?
Genpharmasec Ltd (GENPHARMA) trades at ₹1.18 on NSE and BSE. Market cap ₹81.95 (Cr). Educational data only.
What is the P/E ratio of Genpharmasec Ltd?
Genpharmasec Ltd has a P/E of 149.01x vs industry average 35.45x.
What is the Bull Run score for Genpharmasec Ltd?
Genpharmasec Ltd has a Bull Run score of 11/100 based on 25+ financial parameters.
Does Genpharmasec Ltd pay dividends?
Genpharmasec Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Genpharmasec Ltd?
Genpharmasec Ltd has ROE of 1.90%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Genpharmasec Ltd?
Genpharmasec Ltd has debt-to-equity of 0.17.
Is Genpharmasec Ltd a good investment?
Bull Run gives Genpharmasec Ltd a score of 11/100. This is not investment advice — consult a SEBI-registered advisor.